Clinical Trial

Fat Metabolism

Study Description

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

The gut is able to retain some fat for many hours after a fatty meal. The gut hormone glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is not known how GLP-2 achieves this. One possibility is that GLP-2 increases blood flow in the gut. NG-monomethyl-L-arginine (L-NMMA) is a substance that inhibits nitric oxide synthase (an enzyme that helps make nitric oxide which increases blood flow). This protocol examines whether blocking gut blood flow with L-NMMA is able to prevent GLP-2 from releasing gut lipid stores. Healthy participants will be treated with a combination of Teduglutide (a resistant form of GLP-2) and L-NMMA, and their respective controls. Blood lipid levels will be measured following treatments.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Teduglutide + Normal Saline

Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion

Drug - Teduglutide + L-NMMA

Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

Drug - Placebo + L-NMMA

Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

Additional Information

Official Study Title

Role of a Nitric Oxide Synthase Inhibitor on GLP-2 Mediated Intestinal Lipoprotein Release

Clinical Trial ID

NCT03534661

ParticipAid ID

xboNYa